Androgens modulate the balance between VEGF and angiopoietin expression in prostate epithelial and smooth muscle cells

Prostate

Volumn 50, Issue 2, 2002, Pages 83-91

  Moscatelli, David ^a   Wilson, E Lynette ^a   Tsujimura, Akira ^a   Salm, Sarah N ^a   Koikawa, Yasuhiro ^a   Kim, Gilbert ^a   Richard, Christian ^a  

^a Kaplan Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; HYDROCORTISONE; RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL TYPE; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULARIZATION; WESTERN BLOTTING;

ANDROGENS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; CELL CULTURE TECHNIQUES; ENDOTHELIAL GROWTH FACTORS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; LYMPHOKINES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MUSCLE, SMOOTH; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROTEIN BIOSYNTHESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036468225     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10035     Document Type: Article

References (44)

1. The development of vascular supply of normal rat prostate during the sexual maturation: An angiographic study
2. Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis
3. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats
4. Early effects of castration on the vascular system of the rat ventral prostate gland
5. Androgen receptor localization in different cell types of the adult rat prostate
6. Androgen receptor distribution in rat testis: New implications for androgen regulation of spermatogenesis
7. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor
8. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen
9. Vascular endothelial growth factor and its receptors
10. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
11. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
12. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
13. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
14. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas
15. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121
16. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
17. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
18. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
19. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
20. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
21. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
22. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
23. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
24. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration
25. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats
26. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
27. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers
28. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
29. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens
30. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
31. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
32. Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt
33. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
34. Increased vascularization in mice overexpressing angiopoietin-1
35. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis
36. Generation of active TGF-β by prostatic cell cocultures using novel basal and luminal prostatic epithelial cell lines
37. Transforming growth factor-β is an autocrine mitogen for a novel androgen-responsive murine prostatic smooth muscle cell line, PSMC1
38. A blood-prostate barrier restricts cell and molecular movement across the rat ventral prostate epithelium
39. Overexpression of VEGF in testis and epididymis causes infertility in transgenic mice: Evidence for nonendothelial targets for VEGF
40. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
41. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
42. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth
43. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
44. Functions of the VEGF/VEGF receptor system in the vascular system